Brought to you by 
Sugen licenses TK and TP technology from Max Planck
13 Jul 1999
Executive Summary
The Max Planck Institute for Biochemistry through its licensing arm Garching Innovation GMBH licensed to Sugen (signal transduction) certain tyrosine kinase (TK) and tyrosine phosphatases (TP) technologies.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sugen licenses TK and TP technology from Max Planck
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice